Drug Trial Radar · NCT03719586
Investigational Therapeutics for the Treatment of People With Ebola Virus Disease
Last checked: Nov 20, 2026Latest source record: Sep 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
681
Actual
Start
Nov 21, 2018
Primary completion
Sep 9, 2019
Study completion Aug 18, 2020
Sponsor
- Sponsor type
- NIH
- First posted
- Oct 25, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background: Ebola virus can cause serious illness or death. No medicines are approved to treat it. Researchers need to test new medicines to see if they help people recover from Ebola and are safe to give. They need to test the drugs and compare them in a controlled way. Researchers want to test 4 drugs with people who have Ebola and are in treatment centers. Objective: To study the safety and effectiveness of 4 drugs for people with Ebola virus. Eligibility: People of any age with Ebola infection who are in treatment centers Design: Participants will be screened with questions, medical history, and blood tests. Participants will be randomly assigned to get 1 of 3 study drugs: * ZMapp by IV over about 4 hours. It will be given 3 times, 3 days apart. * Remdesivir by IV over about 1 hour. It will be given once a day for 10 days. * Mab114 by IV for 30-60 minutes. It will be given 1 time. * REGN-EB3 by IV for about 2 hours. It will be given 1 time. For at least a week, participants will stay in isolation in a clinic. They will: * Get supportive care and be monitored * Have a small plastic tube (IV) put in an arm vein for several days to give fluids and collect blood. * Get their study drug. * Be monitored for disease signs and drug side effects. They may get medicines for side effects. * Have blood and urine tests. Participants will stay in the clinic until they finish the study drug and are well enough to leave. Participants will have 2 follow-up visits over 2 months. They will answer questions and give blood and semen samples. ...
Conditions
- Ebola Virus
Interventions
ZMappDrug
Three doses of 50 mg/kg of body weight administered intravenously every third day beginning on Day 1
RemdesivirDrug
Administered intravenously with a loading dose on Day 1 (200 mg for adults and pediatric patients with body weight \>= 40 kg and for pediatric patients weighing \< 40 kg one loading dose of remdesivir 5 mg/kg) followed by 9 to 13 days of once-daily maintenance dosing starting on Day 2 and extending through Day 10 to 14 (100 mg for adults and pediatric patients with body weight \>= 40 kg and for pediatric patients weighing \< 40 kg remdesivir 2.5 mg/kg)
MAb114Drug
50 mg/kg of body weight administered intravenously on Day 1 as a single infusion
REGN-EB3Drug
150 mg/kg of body weight administered intravenously on Day 1 as a single infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- MortalityTime frame: 28 days
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center
Bethesda, Maryland
Ebola Treatment Centers throughout the DRC
Kinshasa Gombe, Democratic Republic of the Congo
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.